nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ABCC1—Mitoxantrone—lymphatic system cancer	0.121	0.188	CbGbCtD
Vandetanib—ABCG2—Teniposide—lymphatic system cancer	0.115	0.18	CbGbCtD
Vandetanib—ABCC1—Vincristine—lymphatic system cancer	0.0829	0.129	CbGbCtD
Vandetanib—ABCG2—Mitoxantrone—lymphatic system cancer	0.0806	0.126	CbGbCtD
Vandetanib—ABCG2—Vincristine—lymphatic system cancer	0.0555	0.0865	CbGbCtD
Vandetanib—ABCC1—Methotrexate—lymphatic system cancer	0.0502	0.0783	CbGbCtD
Vandetanib—ABCG2—Methotrexate—lymphatic system cancer	0.0336	0.0524	CbGbCtD
Vandetanib—CYP3A4—Cytarabine—lymphatic system cancer	0.0253	0.0394	CbGbCtD
Vandetanib—CYP3A4—Teniposide—lymphatic system cancer	0.0249	0.0388	CbGbCtD
Vandetanib—ALB—Methotrexate—lymphatic system cancer	0.0232	0.0361	CbGbCtD
Vandetanib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0174	0.0272	CbGbCtD
Vandetanib—CYP3A4—Vincristine—lymphatic system cancer	0.012	0.0187	CbGbCtD
Vandetanib—Bosutinib—ALK—lymphatic system cancer	0.0118	1	CrCbGaD
Vandetanib—PLK4—Etoposide—Teniposide—lymphatic system cancer	0.00402	0.416	CbGdCrCtD
Vandetanib—ERBB3—Podofilox—Teniposide—lymphatic system cancer	0.004	0.414	CbGdCrCtD
Vandetanib—ERBB3—Vinblastine—Vincristine—lymphatic system cancer	0.00164	0.169	CbGdCrCtD
Vandetanib—Depression—Carmustine—lymphatic system cancer	0.000694	0.00206	CcSEcCtD
Vandetanib—Oedema—Fludarabine—lymphatic system cancer	0.000693	0.00206	CcSEcCtD
Vandetanib—Infection—Fludarabine—lymphatic system cancer	0.000689	0.00204	CcSEcCtD
Vandetanib—Decreased appetite—Teniposide—lymphatic system cancer	0.000686	0.00203	CcSEcCtD
Vandetanib—Renal failure—Carmustine—lymphatic system cancer	0.000684	0.00203	CcSEcCtD
Vandetanib—Vomiting—Mechlorethamine—lymphatic system cancer	0.00068	0.00202	CcSEcCtD
Vandetanib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00068	0.00202	CcSEcCtD
Vandetanib—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00068	0.00202	CcSEcCtD
Vandetanib—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000679	0.00201	CcSEcCtD
Vandetanib—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000678	0.00201	CcSEcCtD
Vandetanib—Stomatitis—Carmustine—lymphatic system cancer	0.000678	0.00201	CcSEcCtD
Vandetanib—Urinary tract infection—Carmustine—lymphatic system cancer	0.000676	0.00201	CcSEcCtD
Vandetanib—Rash—Mechlorethamine—lymphatic system cancer	0.000675	0.002	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000674	0.002	CcSEcCtD
Vandetanib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000674	0.002	CcSEcCtD
Vandetanib—Weight decreased—Vincristine—lymphatic system cancer	0.000674	0.002	CcSEcCtD
Vandetanib—Pneumonia—Vincristine—lymphatic system cancer	0.000668	0.00198	CcSEcCtD
Vandetanib—Depression—Vincristine—lymphatic system cancer	0.000662	0.00196	CcSEcCtD
Vandetanib—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000656	0.00195	CcSEcCtD
Vandetanib—Proteinuria—Methotrexate—lymphatic system cancer	0.000656	0.00195	CcSEcCtD
Vandetanib—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.000654	0.00194	CcSEcCtD
Vandetanib—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000651	0.00193	CcSEcCtD
Vandetanib—Stomatitis—Vincristine—lymphatic system cancer	0.000647	0.00192	CcSEcCtD
Vandetanib—Protein urine present—Methotrexate—lymphatic system cancer	0.000647	0.00192	CcSEcCtD
Vandetanib—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000645	0.00191	CcSEcCtD
Vandetanib—Renal failure—Mitoxantrone—lymphatic system cancer	0.000636	0.00189	CcSEcCtD
Vandetanib—Nausea—Mechlorethamine—lymphatic system cancer	0.000636	0.00189	CcSEcCtD
Vandetanib—Alopecia—Bleomycin—lymphatic system cancer	0.000632	0.00188	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000632	0.00187	CcSEcCtD
Vandetanib—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00063	0.00187	CcSEcCtD
Vandetanib—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000629	0.00187	CcSEcCtD
Vandetanib—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.000629	0.00187	CcSEcCtD
Vandetanib—Haemoglobin—Carmustine—lymphatic system cancer	0.000628	0.00186	CcSEcCtD
Vandetanib—Haemorrhage—Carmustine—lymphatic system cancer	0.000625	0.00185	CcSEcCtD
Vandetanib—Body temperature increased—Teniposide—lymphatic system cancer	0.000624	0.00185	CcSEcCtD
Vandetanib—Abdominal pain—Teniposide—lymphatic system cancer	0.000624	0.00185	CcSEcCtD
Vandetanib—Paraesthesia—Fludarabine—lymphatic system cancer	0.000623	0.00185	CcSEcCtD
Vandetanib—Dyspnoea—Fludarabine—lymphatic system cancer	0.000618	0.00183	CcSEcCtD
Vandetanib—Haematuria—Mitoxantrone—lymphatic system cancer	0.000617	0.00183	CcSEcCtD
Vandetanib—Dyspepsia—Fludarabine—lymphatic system cancer	0.00061	0.00181	CcSEcCtD
Vandetanib—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000607	0.0018	CcSEcCtD
Vandetanib—Decreased appetite—Fludarabine—lymphatic system cancer	0.000603	0.00179	CcSEcCtD
Vandetanib—Visual impairment—Carmustine—lymphatic system cancer	0.000602	0.00179	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000599	0.00178	CcSEcCtD
Vandetanib—Fatigue—Fludarabine—lymphatic system cancer	0.000598	0.00177	CcSEcCtD
Vandetanib—Pain—Fludarabine—lymphatic system cancer	0.000593	0.00176	CcSEcCtD
Vandetanib—Constipation—Fludarabine—lymphatic system cancer	0.000593	0.00176	CcSEcCtD
Vandetanib—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000591	0.00175	CcSEcCtD
Vandetanib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000589	0.00175	CcSEcCtD
Vandetanib—Respiratory failure—Methotrexate—lymphatic system cancer	0.000587	0.00174	CcSEcCtD
Vandetanib—Urethral disorder—Vincristine—lymphatic system cancer	0.000584	0.00173	CcSEcCtD
Vandetanib—Eye disorder—Carmustine—lymphatic system cancer	0.000584	0.00173	CcSEcCtD
Vandetanib—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000584	0.00173	CcSEcCtD
Vandetanib—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000581	0.00172	CcSEcCtD
Vandetanib—Asthenia—Teniposide—lymphatic system cancer	0.000566	0.00168	CcSEcCtD
Vandetanib—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000563	0.00167	CcSEcCtD
Vandetanib—Pruritus—Teniposide—lymphatic system cancer	0.000558	0.00166	CcSEcCtD
Vandetanib—Arrhythmia—Carmustine—lymphatic system cancer	0.000558	0.00166	CcSEcCtD
Vandetanib—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000556	0.00165	CcSEcCtD
Vandetanib—Cystitis—Methotrexate—lymphatic system cancer	0.000556	0.00165	CcSEcCtD
Vandetanib—Cardiac disorder—Vincristine—lymphatic system cancer	0.000553	0.00164	CcSEcCtD
Vandetanib—Alopecia—Carmustine—lymphatic system cancer	0.000552	0.00164	CcSEcCtD
Vandetanib—Body temperature increased—Fludarabine—lymphatic system cancer	0.000548	0.00163	CcSEcCtD
Vandetanib—Mental disorder—Carmustine—lymphatic system cancer	0.000547	0.00162	CcSEcCtD
Vandetanib—Malnutrition—Carmustine—lymphatic system cancer	0.000544	0.00161	CcSEcCtD
Vandetanib—Cough—Bleomycin—lymphatic system cancer	0.000544	0.00161	CcSEcCtD
Vandetanib—Angiopathy—Vincristine—lymphatic system cancer	0.000541	0.0016	CcSEcCtD
Vandetanib—Diarrhoea—Teniposide—lymphatic system cancer	0.00054	0.0016	CcSEcCtD
Vandetanib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000537	0.00159	CcSEcCtD
Vandetanib—Chest pain—Bleomycin—lymphatic system cancer	0.00053	0.00157	CcSEcCtD
Vandetanib—Alopecia—Vincristine—lymphatic system cancer	0.000527	0.00156	CcSEcCtD
Vandetanib—Mental disorder—Vincristine—lymphatic system cancer	0.000522	0.00155	CcSEcCtD
Vandetanib—Bladder pain—Methotrexate—lymphatic system cancer	0.000521	0.00155	CcSEcCtD
Vandetanib—Neoplasm—Methotrexate—lymphatic system cancer	0.000521	0.00155	CcSEcCtD
Vandetanib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000519	0.00154	CcSEcCtD
Vandetanib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000513	0.00152	CcSEcCtD
Vandetanib—Vision blurred—Carmustine—lymphatic system cancer	0.000512	0.00152	CcSEcCtD
Vandetanib—Tremor—Carmustine—lymphatic system cancer	0.000509	0.00151	CcSEcCtD
Vandetanib—Oedema—Bleomycin—lymphatic system cancer	0.000508	0.00151	CcSEcCtD
Vandetanib—Infection—Bleomycin—lymphatic system cancer	0.000505	0.0015	CcSEcCtD
Vandetanib—Vomiting—Teniposide—lymphatic system cancer	0.000502	0.00149	CcSEcCtD
Vandetanib—Sepsis—Methotrexate—lymphatic system cancer	0.0005	0.00148	CcSEcCtD
Vandetanib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000498	0.00148	CcSEcCtD
Vandetanib—Asthenia—Fludarabine—lymphatic system cancer	0.000497	0.00148	CcSEcCtD
Vandetanib—Rash—Teniposide—lymphatic system cancer	0.000497	0.00148	CcSEcCtD
Vandetanib—Dermatitis—Teniposide—lymphatic system cancer	0.000497	0.00147	CcSEcCtD
Vandetanib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000495	0.00147	CcSEcCtD
Vandetanib—Headache—Teniposide—lymphatic system cancer	0.000494	0.00147	CcSEcCtD
Vandetanib—Pruritus—Fludarabine—lymphatic system cancer	0.000491	0.00146	CcSEcCtD
Vandetanib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000476	0.00141	CcSEcCtD
Vandetanib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000474	0.00141	CcSEcCtD
Vandetanib—Convulsion—Carmustine—lymphatic system cancer	0.000471	0.0014	CcSEcCtD
Vandetanib—Hypertension—Carmustine—lymphatic system cancer	0.000469	0.00139	CcSEcCtD
Vandetanib—Nausea—Teniposide—lymphatic system cancer	0.000469	0.00139	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000463	0.00137	CcSEcCtD
Vandetanib—Chest pain—Carmustine—lymphatic system cancer	0.000463	0.00137	CcSEcCtD
Vandetanib—Anxiety—Carmustine—lymphatic system cancer	0.000461	0.00137	CcSEcCtD
Vandetanib—Paraesthesia—Bleomycin—lymphatic system cancer	0.000456	0.00135	CcSEcCtD
Vandetanib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000453	0.00134	CcSEcCtD
Vandetanib—Convulsion—Vincristine—lymphatic system cancer	0.00045	0.00133	CcSEcCtD
Vandetanib—Hypertension—Vincristine—lymphatic system cancer	0.000448	0.00133	CcSEcCtD
Vandetanib—Oedema—Carmustine—lymphatic system cancer	0.000444	0.00132	CcSEcCtD
Vandetanib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000442	0.00131	CcSEcCtD
Vandetanib—Cough—Mitoxantrone—lymphatic system cancer	0.000441	0.00131	CcSEcCtD
Vandetanib—Infection—Carmustine—lymphatic system cancer	0.000441	0.00131	CcSEcCtD
Vandetanib—Vomiting—Fludarabine—lymphatic system cancer	0.000441	0.00131	CcSEcCtD
Vandetanib—Convulsion—Mitoxantrone—lymphatic system cancer	0.000438	0.0013	CcSEcCtD
Vandetanib—Rash—Fludarabine—lymphatic system cancer	0.000437	0.0013	CcSEcCtD
Vandetanib—Dermatitis—Fludarabine—lymphatic system cancer	0.000437	0.0013	CcSEcCtD
Vandetanib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000436	0.00129	CcSEcCtD
Vandetanib—Pain—Bleomycin—lymphatic system cancer	0.000435	0.00129	CcSEcCtD
Vandetanib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000434	0.00129	CcSEcCtD
Vandetanib—Headache—Fludarabine—lymphatic system cancer	0.000434	0.00129	CcSEcCtD
Vandetanib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00043	0.00128	CcSEcCtD
Vandetanib—Chest pain—Mitoxantrone—lymphatic system cancer	0.00043	0.00128	CcSEcCtD
Vandetanib—Anxiety—Mitoxantrone—lymphatic system cancer	0.000429	0.00127	CcSEcCtD
Vandetanib—Lethargy—Methotrexate—lymphatic system cancer	0.000427	0.00127	CcSEcCtD
Vandetanib—Oedema—Vincristine—lymphatic system cancer	0.000424	0.00126	CcSEcCtD
Vandetanib—Infection—Vincristine—lymphatic system cancer	0.000421	0.00125	CcSEcCtD
Vandetanib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000415	0.00123	CcSEcCtD
Vandetanib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000415	0.00123	CcSEcCtD
Vandetanib—Oedema—Mitoxantrone—lymphatic system cancer	0.000413	0.00122	CcSEcCtD
Vandetanib—Nausea—Fludarabine—lymphatic system cancer	0.000412	0.00122	CcSEcCtD
Vandetanib—Infection—Mitoxantrone—lymphatic system cancer	0.00041	0.00122	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000404	0.0012	CcSEcCtD
Vandetanib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000404	0.0012	CcSEcCtD
Vandetanib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000402	0.00119	CcSEcCtD
Vandetanib—Insomnia—Carmustine—lymphatic system cancer	0.000401	0.00119	CcSEcCtD
Vandetanib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000401	0.00119	CcSEcCtD
Vandetanib—Paraesthesia—Carmustine—lymphatic system cancer	0.000398	0.00118	CcSEcCtD
Vandetanib—Dyspnoea—Carmustine—lymphatic system cancer	0.000396	0.00117	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000386	0.00115	CcSEcCtD
Vandetanib—Decreased appetite—Carmustine—lymphatic system cancer	0.000386	0.00114	CcSEcCtD
Vandetanib—Insomnia—Vincristine—lymphatic system cancer	0.000383	0.00114	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000383	0.00114	CcSEcCtD
Vandetanib—Paraesthesia—Vincristine—lymphatic system cancer	0.00038	0.00113	CcSEcCtD
Vandetanib—Pain—Carmustine—lymphatic system cancer	0.000379	0.00113	CcSEcCtD
Vandetanib—Constipation—Carmustine—lymphatic system cancer	0.000379	0.00113	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000376	0.00112	CcSEcCtD
Vandetanib—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00037	0.0011	CcSEcCtD
Vandetanib—Decreased appetite—Vincristine—lymphatic system cancer	0.000368	0.00109	CcSEcCtD
Vandetanib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000368	0.00109	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000366	0.00109	CcSEcCtD
Vandetanib—Fatigue—Vincristine—lymphatic system cancer	0.000365	0.00108	CcSEcCtD
Vandetanib—Asthenia—Bleomycin—lymphatic system cancer	0.000365	0.00108	CcSEcCtD
Vandetanib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000363	0.00108	CcSEcCtD
Vandetanib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000363	0.00108	CcSEcCtD
Vandetanib—Constipation—Vincristine—lymphatic system cancer	0.000362	0.00107	CcSEcCtD
Vandetanib—Pain—Vincristine—lymphatic system cancer	0.000362	0.00107	CcSEcCtD
Vandetanib—Pruritus—Bleomycin—lymphatic system cancer	0.00036	0.00107	CcSEcCtD
Vandetanib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000359	0.00106	CcSEcCtD
Vandetanib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000356	0.00106	CcSEcCtD
Vandetanib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000354	0.00105	CcSEcCtD
Vandetanib—Pain—Mitoxantrone—lymphatic system cancer	0.000353	0.00105	CcSEcCtD
Vandetanib—Constipation—Mitoxantrone—lymphatic system cancer	0.000353	0.00105	CcSEcCtD
Vandetanib—Abdominal pain—Carmustine—lymphatic system cancer	0.000351	0.00104	CcSEcCtD
Vandetanib—Body temperature increased—Carmustine—lymphatic system cancer	0.000351	0.00104	CcSEcCtD
Vandetanib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000346	0.00103	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—lymphatic system cancer	0.000338	0.001	CcSEcCtD
Vandetanib—Neutropenia—Methotrexate—lymphatic system cancer	0.000338	0.001	CcSEcCtD
Vandetanib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000337	0.001	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000336	0.000997	CcSEcCtD
Vandetanib—Body temperature increased—Vincristine—lymphatic system cancer	0.000335	0.000994	CcSEcCtD
Vandetanib—Abdominal pain—Vincristine—lymphatic system cancer	0.000335	0.000994	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00033	0.000979	CcSEcCtD
Vandetanib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000326	0.000968	CcSEcCtD
Vandetanib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000326	0.000968	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—lymphatic system cancer	0.000324	0.000962	CcSEcCtD
Vandetanib—Vomiting—Bleomycin—lymphatic system cancer	0.000323	0.000959	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000322	0.000956	CcSEcCtD
Vandetanib—Infestation—Methotrexate—lymphatic system cancer	0.000322	0.000956	CcSEcCtD
Vandetanib—Depression—Methotrexate—lymphatic system cancer	0.000321	0.000953	CcSEcCtD
Vandetanib—Rash—Bleomycin—lymphatic system cancer	0.000321	0.000951	CcSEcCtD
Vandetanib—Dermatitis—Bleomycin—lymphatic system cancer	0.00032	0.00095	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000319	0.000948	CcSEcCtD
Vandetanib—Asthenia—Carmustine—lymphatic system cancer	0.000318	0.000945	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—lymphatic system cancer	0.000317	0.00094	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—lymphatic system cancer	0.000314	0.000932	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000313	0.000929	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—lymphatic system cancer	0.000307	0.000912	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000305	0.000904	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—lymphatic system cancer	0.000304	0.000902	CcSEcCtD
Vandetanib—Asthenia—Vincristine—lymphatic system cancer	0.000304	0.000902	CcSEcCtD
Vandetanib—Diarrhoea—Carmustine—lymphatic system cancer	0.000304	0.000901	CcSEcCtD
Vandetanib—Nausea—Bleomycin—lymphatic system cancer	0.000302	0.000896	CcSEcCtD
Vandetanib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000296	0.000878	CcSEcCtD
Vandetanib—Dizziness—Carmustine—lymphatic system cancer	0.000293	0.000871	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000291	0.000863	CcSEcCtD
Vandetanib—Diarrhoea—Vincristine—lymphatic system cancer	0.00029	0.00086	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000289	0.000858	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000286	0.000848	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000284	0.000841	CcSEcCtD
Vandetanib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000282	0.000837	CcSEcCtD
Vandetanib—Vomiting—Carmustine—lymphatic system cancer	0.000282	0.000837	CcSEcCtD
Vandetanib—Dizziness—Vincristine—lymphatic system cancer	0.00028	0.000831	CcSEcCtD
Vandetanib—Rash—Carmustine—lymphatic system cancer	0.00028	0.00083	CcSEcCtD
Vandetanib—Dermatitis—Carmustine—lymphatic system cancer	0.00028	0.000829	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—lymphatic system cancer	0.000279	0.000827	CcSEcCtD
Vandetanib—Headache—Carmustine—lymphatic system cancer	0.000278	0.000825	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000274	0.000812	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—lymphatic system cancer	0.00027	0.000802	CcSEcCtD
Vandetanib—Vomiting—Vincristine—lymphatic system cancer	0.000269	0.000799	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000268	0.000797	CcSEcCtD
Vandetanib—Rash—Vincristine—lymphatic system cancer	0.000267	0.000792	CcSEcCtD
Vandetanib—Dermatitis—Vincristine—lymphatic system cancer	0.000267	0.000792	CcSEcCtD
Vandetanib—Headache—Vincristine—lymphatic system cancer	0.000265	0.000787	CcSEcCtD
Vandetanib—Nausea—Carmustine—lymphatic system cancer	0.000264	0.000782	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—lymphatic system cancer	0.000262	0.000779	CcSEcCtD
Vandetanib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000262	0.000778	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000261	0.000774	CcSEcCtD
Vandetanib—Rash—Mitoxantrone—lymphatic system cancer	0.00026	0.000772	CcSEcCtD
Vandetanib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00026	0.000771	CcSEcCtD
Vandetanib—Headache—Mitoxantrone—lymphatic system cancer	0.000258	0.000767	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—lymphatic system cancer	0.000256	0.000758	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—lymphatic system cancer	0.000253	0.000752	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—lymphatic system cancer	0.000252	0.000747	CcSEcCtD
Vandetanib—Nausea—Vincristine—lymphatic system cancer	0.000252	0.000747	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000247	0.000732	CcSEcCtD
Vandetanib—Nausea—Mitoxantrone—lymphatic system cancer	0.000245	0.000727	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—lymphatic system cancer	0.000237	0.000704	CcSEcCtD
Vandetanib—Cough—Methotrexate—lymphatic system cancer	0.00022	0.000652	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—lymphatic system cancer	0.000218	0.000647	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—lymphatic system cancer	0.000214	0.000636	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—lymphatic system cancer	0.000214	0.000636	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000213	0.000632	CcSEcCtD
Vandetanib—Infection—Methotrexate—lymphatic system cancer	0.000204	0.000606	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000202	0.000598	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000201	0.000597	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—lymphatic system cancer	0.0002	0.000592	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000187	0.000556	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—lymphatic system cancer	0.000186	0.000552	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—lymphatic system cancer	0.000185	0.000548	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—lymphatic system cancer	0.000183	0.000544	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—lymphatic system cancer	0.000181	0.000537	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000179	0.00053	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000177	0.000526	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—lymphatic system cancer	0.000177	0.000526	CcSEcCtD
Vandetanib—Pain—Methotrexate—lymphatic system cancer	0.000176	0.000521	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000168	0.000499	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000162	0.000482	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000162	0.000482	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—lymphatic system cancer	0.000147	0.000438	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—lymphatic system cancer	0.000145	0.000431	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—lymphatic system cancer	0.000141	0.000417	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—lymphatic system cancer	0.000136	0.000403	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—lymphatic system cancer	0.000131	0.000388	CcSEcCtD
Vandetanib—Rash—Methotrexate—lymphatic system cancer	0.00013	0.000385	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—lymphatic system cancer	0.000129	0.000384	CcSEcCtD
Vandetanib—Headache—Methotrexate—lymphatic system cancer	0.000129	0.000382	CcSEcCtD
Vandetanib—Nausea—Methotrexate—lymphatic system cancer	0.000122	0.000362	CcSEcCtD
